Ultragenyx Pharma (RARE) Announces rhGUS Phase 3 Met Primary Endpoint in Sly Syndrome
Tweet Send to a Friend
Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) announced positive topline data from the pivotal Phase ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
